Richard S.E. Keefe

Schizophrenia, psychosis, cognition, pharmacologic treatment of cognitive impairment, sport psychology, functional imaging (PET, fMRI), frontal cortex, motor functions.

Current Appointments & Affiliations

Professor Emeritus in Psychiatry and Behavioral Sciences · 2022 - Present Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences, Psychiatry & Behavioral Sciences

Faculty Network Member of the Duke Institute for Brain Sciences · 2008 - Present Duke Institute for Brain Sciences, University Institutes and Centers

In the News

Published November 19, 2019

Global List of Highly Cited Puts Duke in Top Ten

Published November 27, 2018

Duke Faculty Plentiful On ‘Highly Cited’ List

Published April 24, 2014

Richard Keefe: Bruce Springsteen offers chance to recall impulsiveness of teen brains

View All News

Recent Publications

Assessing the inter-rater reliability of the Schizophrenia Cognition Rating Scale: a non-interventional quantitative study

Journal Article Schizophrenia · December 1, 2025 Background: Cognitive impairment is a core feature of schizophrenia, profoundly impacting patients’ functional abilities. As such, evaluating cognition-related functional activity/impairment is essential for identifying effective treatments. This study pre ... Full text Cite

Assessment of the German Version of Brief Assessment of Cognition in Schizophrenia (BACS)

Journal Article Schizophrenia Research: Cognition · September 1, 2025 Background: Cognitive impairments are a hallmark of schizophrenia-spectrum disorders (SSD), contributing to poor treatment outcomes and a key treatment target. The Brief Assessment of Cognition in Schizophrenia (BACS) battery is a validated tool designed t ... Full text Cite

Commentary.

Journal Article Schizophr Bull · March 14, 2025 Full text Link to item Cite

View All Publications

Recent Grants

A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early intervention in patients with attenuated psychosis syndrom

Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2017 - 2021

Auditory Perception and Emotion Recognition in Young People at Risk for Psychosis

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2016 - 2019

Study to Evaulate the Kappa Opioid Receptor as a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluating Whether LY2456302 Engages Reward-related Neural Circuitry.

Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2013 - 2017

View All Grants

Education, Training & Certifications

New York University · 1990 Ph.D.